{"id":"https://openalex.org/W2581345006","doi":"https://doi.org/10.1182/blood.v114.22.2670.2670","title":"Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients.","display_name":"Population Pharmacokinetics of Siplizumab (MEDI-507), a Humanized Anti-CD2 Monoclonal Antibody, in Cancer Patients.","publication_year":2009,"publication_date":"2009-11-20","ids":{"openalex":"https://openalex.org/W2581345006","doi":"https://doi.org/10.1182/blood.v114.22.2670.2670","mag":"2581345006"},"language":"en","primary_location":{"id":"doi:10.1182/blood.v114.22.2670.2670","doi":"https://doi.org/10.1182/blood.v114.22.2670.2670","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.2670.2670","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5100697162","display_name":"Chunlin Chen","orcid":"https://orcid.org/0000-0002-1708-3047","observed_orcids":["https://orcid.org/0000-0002-1708-3047","https://orcid.org/0000-0002-7140-5668"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Chunlin Chen","raw_affiliation_strings":["Translational Science, Medimmune, Gaithersburg, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Translational Science, Medimmune, Gaithersburg, MD, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113663097","display_name":"John Edward Janik","orcid":"https://orcid.org/0000-0001-9208-9660","observed_orcids":["https://orcid.org/0000-0001-9208-9660"]},"institutions":[{"id":"https://openalex.org/I4210140884","display_name":"National Cancer Institute","ror":"https://ror.org/040gcmg81","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884"]},{"id":"https://openalex.org/I4210149717","display_name":"Center for Cancer Research","ror":"https://ror.org/05bjen692","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210140884","https://openalex.org/I4210149717"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"John E Janik","raw_affiliation_strings":["Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA,","institution_ids":["https://openalex.org/I4210140884","https://openalex.org/I4210149717"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025784315","display_name":"Karen Kaucic","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Karen Kaucic","raw_affiliation_strings":["Medimmune, Inc., Gaithersburg, MD, USA,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medimmune, Inc., Gaithersburg, MD, USA,","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069627913","display_name":"Lorin K. Roskos","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Lorin Roskos","raw_affiliation_strings":["Medimmune, Gaithersburg, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medimmune, Gaithersburg, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071837295","display_name":"Bahija Jallal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Bahija Jallal","raw_affiliation_strings":["Medimmune, Gaithersburg, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medimmune, Gaithersburg, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083919448","display_name":"Gabriel J. Robbie","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Gabriel J. Robbie","raw_affiliation_strings":["Medimmune, Gaithersburg, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medimmune, Gaithersburg, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5069627913","https://openalex.org/A5071837295","https://openalex.org/A5083919448","https://openalex.org/A5100697162","https://openalex.org/A5113663097"],"corresponding_institution_ids":["https://openalex.org/I4210140884","https://openalex.org/I4210149717"],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.3990605,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"114","issue":"22","first_page":"2670","last_page":"2670"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.823199987411499,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.823199987411499,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.08529999852180481,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.015200000256299973,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/population-pharmacokinetics","display_name":"population pharmacokinetics","score":0.800000011920929},{"id":"https://openalex.org/keywords/anti-cd2-monoclonal-antibody","display_name":"anti-CD2 monoclonal antibody","score":0.9509999752044678},{"id":"https://openalex.org/keywords/cancer-patients","display_name":"cancer patients","score":0.5720000267028809},{"id":"https://openalex.org/keywords/nonlinear-elimination","display_name":"nonlinear elimination","score":0.6060000061988831},{"id":"https://openalex.org/keywords/volume-of-distribution","display_name":"volume of distribution","score":0.7129999995231628},{"id":"https://openalex.org/keywords/clearance","display_name":"clearance","score":0.6079999804496765},{"id":"https://openalex.org/keywords/lymphoproliferative-disorders","display_name":"lymphoproliferative disorders","score":0.7419999837875366},{"id":"https://openalex.org/keywords/nonlinear-mixed-effects-models","display_name":"nonlinear mixed-effects models","score":0.6330000162124634},{"id":"https://openalex.org/keywords/generalized-additive-models","display_name":"generalized additive models","score":0.6200000047683716},{"id":"https://openalex.org/keywords/covariate-selection","display_name":"covariate selection","score":0.5960000157356262},{"id":"https://openalex.org/keywords/two-compartment-model","display_name":"two-compartment model","score":0.6269999742507935},{"id":"https://openalex.org/keywords/inter-individual-variability","display_name":"interindividual variability","score":0.5199999809265137}],"concepts":[{"id":"https://openalex.org/C2776239304","wikidata":"https://www.wikidata.org/wiki/Q6954915","display_name":"NONMEM","level":3,"score":0.8868176937103271},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7954770922660828},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6425408720970154},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.581512451171875},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46322062611579895},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4520258605480194},{"id":"https://openalex.org/C119043178","wikidata":"https://www.wikidata.org/wiki/Q320723","display_name":"Covariate","level":2,"score":0.43953847885131836},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3858247399330139},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3852285146713257},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37572482228279114},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3556916117668152},{"id":"https://openalex.org/C105795698","wikidata":"https://www.wikidata.org/wiki/Q12483","display_name":"Statistics","level":1,"score":0.14453884959220886},{"id":"https://openalex.org/C33923547","wikidata":"https://www.wikidata.org/wiki/Q395","display_name":"Mathematics","level":0,"score":0.11362037062644958},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood.v114.22.2670.2670","doi":"https://doi.org/10.1182/blood.v114.22.2670.2670","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood.v114.22.2670.2670","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9907000064849854,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2955099056","https://openalex.org/W1965511179","https://openalex.org/W2011055527","https://openalex.org/W2978526561","https://openalex.org/W4308183799","https://openalex.org/W2191550991","https://openalex.org/W4403289092","https://openalex.org/W3137991873","https://openalex.org/W4322616597","https://openalex.org/W2072624086"],"abstract_inverted_index":{"Abstract":[0,1],"2670":[2],"Poster":[3],"Board":[4],"II-646":[5],"Introduction:":[6],"Siplizumab,":[7],"a":[8,41,95,107,178,215,290,337,393],"humanized":[9],"IgG1k":[10],"class":[11],"monoclonal":[12],"antibody":[13],"that":[14,51],"targets":[15],"CD2":[16],"expressing":[17],"T-and":[18],"NK-cells,":[19],"was":[20,38,68,104,191,211,253,265,287,333],"evaluated":[21],"in":[22,27,56,70,155,174,187,320,366,379],"phase":[23],"I":[24],"dose-escalation":[25,66],"trials":[26],"patients":[28,72,173,286,298],"with":[29,113,200,219,222,256,357,387],"CD2-positive":[30],"lymphoproliferative":[31],"disorder.":[32],"The":[33,209,247,327,362,382],"objective":[34],"of":[35,84,97,180,230,260,284,295,305,307,331,354,398,408],"this":[36,380],"study":[37,67,176],"to":[39,350,372,377,395,410],"develop":[40],"population":[42,248,383],"pharmacokinetic":[43,58,217],"(PK)":[44],"model":[45,218,234,242,385],"for":[46,94,153,250,402],"siplizumab":[47,57,85,188,332],"and":[48,133,161,196,225,233,241,262,272,279,302,310,317,347],"identify":[49],"covariates":[50,127],"could":[52,390],"explain":[53],"the":[54,147,158,175,194,285],"variability":[55,258],"parameters.":[59],"Methods:":[60],"A":[61],"Phase":[62],"1,":[63],"open":[64],"label,":[65],"conducted":[69],"29":[71,172],"(14":[73],"males/15":[74],"females,":[75],"age":[76],"range":[77],"34\u201379":[78],"years)":[79],"who":[80],"received":[81],"0.2\u20134.8":[82],"mg/kg":[83],"as":[86,289,392],"1-3":[87],"consecutive":[88],"daily":[89],"doses":[90],"every":[91],"14":[92],"days":[93],"total":[96,179],"1-8":[98],"cycles.":[99],"Siplizumab":[100,166],"serum":[101,182,189,201,244,328],"concentration":[102,183,245],"data":[103,210,389],"analyzed":[105],"using":[106,138,157],"nonlinear":[108],"mixed":[109],"effects":[110],"modeling":[111],"approach":[112],"software":[114],"(NONMEM).":[115],"Based":[116],"on":[117],"exploratory":[118],"analysis,":[119],"1-and":[120],"2-compartment":[121],"non-linear":[122,226,339],"models":[123],"were":[124,136,150,168,274,344],"evaluated.":[125],"Demographic":[126],"including":[128],"body":[129,374],"weight,":[130],"age,":[131],"sex":[132],"race":[134],"(Caucasian/Black/Asian)":[135],"screened":[137],"Generalized":[139],"Additive":[140],"Model":[141],"(GAM)":[142],"analysis.":[143],"Covariates":[144],"selected":[145],"during":[146],"GAM":[148],"analysis":[149],"further":[151],"tested":[152],"significance":[154],"NONMEM":[156],"forward":[159],"inclusion":[160],"backward":[162],"elimination":[163,227,269],"approach.":[164],"Results:":[165],"concentrations":[167,190,202],"obtained":[169],"from":[170],"all":[171],"yielding":[177],"619":[181],"observations.":[184],"Pronounced":[185],"non-linearity":[186],"observed":[192,240],"after":[193],"initial":[195],"later":[197],"dosing":[198],"cycles,":[199],"declining":[203],"faster":[204],"at":[205],"lower":[206,363,373],"dose":[207,400],"levels.":[208],"best":[212],"described":[213,335],"by":[214,336],"two-compartment":[216,338],"zero-order":[220],"input":[221],"parallel":[223],"linear":[224,251],"pathways.":[228],"Goodness":[229],"fit":[231],"plots":[232],"diagnostics":[235],"indicated":[236],"good":[237],"agreement":[238],"between":[239],"predicted":[243],"values.":[246],"estimates":[249],"clearance":[252,264],"0.168":[254],"L/day":[255],"inter-subject":[257],"(ISV)":[259],"50%,":[261],"inter-compartmental":[263],"2.83":[266],"L/day.":[267],"Nonlinear":[268],"parameters,":[270],"Vmax":[271],"Km":[273],"10.32":[275],"mcg/day":[276],"(56%":[277],"ISV)":[278],"51.8":[280],"mcg/L,":[281],"respectively.":[282],"Sex":[283],"identified":[288],"significant":[291,358],"covariate":[292],"impacting":[293],"volumes":[294,304],"distribution.":[296],"Male":[297],"had":[299],"higher":[300],"central":[301],"peripheral":[303],"distribution":[306,365],"2.8":[308],"L":[309,316,319],"3.0":[311],"L,":[312],"respectively,":[313],"compared":[314,376],"to1.38":[315],"2.4":[318],"females":[321,367],"[32%":[322],"vs":[323],"50%":[324],"ISV].":[325],"Conclusion:":[326],"concentration-time":[329],"profile":[330],"adequately":[334],"PK":[340,352,384],"model.":[341],"Population":[342],"parameters":[343],"precisely":[345],"estimated":[346],"correspond":[348],"well":[349],"reported":[351],"behaviour":[353],"monocolonal":[355],"antibodies":[356],"target":[359],"mediated":[360],"elimination.":[361],"volume":[364],"is":[368],"most":[369],"likely":[370],"due":[371],"weight":[375],"males":[378],"study.":[381],"combined":[386],"pharmacodynamic":[388],"serve":[391],"tool":[394],"guide":[396],"selection":[397],"optimal":[399],"regimens":[401],"siplizumab.":[403],"Disclosures:":[404],"No":[405],"relevant":[406],"conflicts":[407],"interest":[409],"declare.":[411]},"counts_by_year":[],"updated_date":"2026-09-24T07:57:37.273135","created_date":"2017-02-03T00:00:00"}